FzioMed, Inc. News

Confirmatory Clinical Study to Support the Effectiveness and Safety of Oxiplex® for the Reduction of Pain and Symptoms Following Lumbar Surgery

FzioMed is pleased to announce the enrollment of patient number one in the supportive study of Oxiplex® in patients undergoing lumbar surgery for disc herniation SAN LUIS OBISPO, Calif., July 23, 2018 -- Oxiplex® is an absorbable, synthetic viscoelastic gel that is applied following partial discectomy, with the intent to reduce postoperative leg pain, back pain and …

Read More

FzioMed Announces 500,000 Units of Oxiplex® Shipped Worldwide

SAN LUIS OBISPO, Calif.--(BUSINESS WIRE)--FzioMed, Inc. a leading biomaterials company, is pleased to announce that Oxiplex sales have now passed the 500,000 unit mark. Oxiplex is approved outside the United States in more than 70 countries and distributed under various brand names; including, Oxiplex, Oxiplex/SP, MediShield, and Interpose. Oxiplex is an absorbable gel applied to …

Read More

FzioMed Receives FDA Approval for Small Confirmatory Study of Oxiplex® in Patients Undergoing Lumbar Surgery for Disc Herniation

Confirmatory Clinical Study to Support the Effectiveness and Safety of Oxiplex® for the Reduction of Pain and Symptoms Following Lumbar Surgery. SAN LUIS OBISPO, Calif.--(BUSINESS WIRE)--FzioMed, Inc., a biomaterials company celebrating 21 years in business, has received approval from FDA to conduct a small confirmatory study of Oxiplex® in the United States. Oxiplex® is an …

Read More

FzioMed Patent US 9,636,434, May 2,2017

COMPOSITIONS OF CARBOXYMETHYLCELLULOSE AND POLYETHYLENE OXIDE IONICALLY CROSS-LINKED USING POLYHYDROXYL ORGANIC ANIONS. San Luis Obispo, California, May 2, 2017. FzioMed, which celebrates 21 years in business this year has received a new  patent, US 9,636,434. Methods for manufacturing ionically cross-linked compositions of carboxypolysaccharides, polyalkylene oxides,polyhydroxyl organic anions, optionally divalent cations and aqueous media are also …

Read More

Visit FzioMed at these Conferences in 2017

Meeting Name Dates    Location Global Congress on Hysteroscopy 5/2 - 5/5/2017 Barcelona, Spain FESSH 6/21 – 6/24/2017 Budapest, Hungary Eurospine 10/11 – 10/13/2017 Dublin, Ireland NASS 10/25 – 10/28/2017 Orlando, FL AAGL 11/12 – 11/16/2017 Washington, DC

Read More

Visit FzioMed at these Conferences in 2016

Mar 3 - 5 AAOS Orlando, FL Apr 6 - 8 ISASS Las Vegas, NV May 16 - 20 Spineweek 2016 Singapore Jun 22 - 25 FESSH Santander, Spain Oct 2 - 5 ESGE Brussels, Belgium Oct 5 - 7 Eurospine Berlin, Germany Oct 26 - 28 NASS Boston, MA Nov 14 - 18 AAGL …

Read More

FzioMed Patent US 9,161,987 B2 Carboxymethylcellulose/Polyethylene Glycol Compositions for Medical Uses.

SAN LUIS OBISPO, California, November 2nd 2015. FzioMed, Inc., which recently celebrated 19 years in the medical device business, has received a new patent, US 9,161,987 B2, for crosslinked compositions of carboxymethylcellulose (CMC) and polyethylene glycol (PEG) for medical uses.  The crosslinking technology provides devices that can be made with a variety of viscoelastic properties, to …

Read More

FzioMed Announces Sale of 400,000th Unit of Oxiplex

SAN LUIS OBISPO, California – July 7th, 2015 - FzioMed, Inc. (www.fziomed.com) announced that it has shipped the 400,000th unit of Oxiplex® gel.  Oxiplex is approved outside the United States in 70 countries and is distributed under the brand names Oxiplex®, Oxiplex®/SP and MediShield™. Oxiplex is an absorbable gel that is applied to spinal nerve …

Read More

Visit FzioMed at these Conferences in 2015

Jun 17 - 20 XX FESSH Congress Federation of European Societies for Surgery of the Hand XX FESSH Congress 17-20 June 2015 Milan, Italy 18th of June, 13.00h – Green Room N.3 FZIOMED SYMPOSIUM THE PREVENTION AND TREATMENT OF T/N ADHESIONS  IN HAND SURGERY STATE OF THE ART Chairmen: Michele Riccio, Gian Carlo Caruso Adhesion …

Read More

FzioMed Inc announces new patent issuance in the European Union.

SAN LUIS OBISPO, California—July 21st, 2014—FzioMed, Inc., a manufacturer and marketer of synthetic biomaterials is pleased to announce the issuance of a new patent in Europe, ‘Chemically Activated Carboxypolysaccharides and Uses’. This invention relates to derivatized carboxypolysaccharides (CPS) and their uses in gels and films incorporating polyethylene oxide (PEO) for drug delivery, and for hemostatic …

Read More

FzioMed, Inc. Announces Postponement of Dispute Resolution Panel for Oxiplex PMA

SAN LUIS OBISPO, California—May 28th, 2014— FzioMed, Inc. today announced it has agreed with the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) to postpone the Dispute Resolution Panel for its Oxiplex PMA; the meeting was previously scheduled for June 10.  The postponement was agreed between the parties …

Read More

FzioMed Announces Date for Medical Device Dispute Resolution Panel on Oxiplex®

Already approved in 70 Countries, Medical Device Dispute Resolution Panel will Weigh Whether Oxiplex Should Also be Made Available in the U.S. SAN LUIS OBISPO, California—April 11th, 2014—FzioMed, Inc., a medical device manufacturer specializing in biomaterials, has received notification from FDA that the Medical Device Dispute Resolution Panel (MDDRP) will convene and make a decision …

Read More

FDA Grants FzioMed an Independent Review of its Oxiplex® Gel by the Medical Devices Dispute Resolution Panel

Approved in 70 Countries, Panel will Weigh Whether Oxiplex Should Also be Available in the U.S. SAN LUIS OBISPO, California—November 4th, 2013—FzioMed, a medical device company that recently celebrated the 17th anniversary of its founding, has received approval from the Commissioner of the U. S. Food and Drug Administration of its Petition for an independent …

Read More

FzioMed receives approval for Dynavisc® in Australia

SAN LUIS OBISPO, California – May 6th 2013 - FzioMed, a privately held medical device company based in San Luis Obispo, CA., is pleased to announce the inclusion of Dynavisc on the Australian Register of Therapeutic Goods (ARTG). Dynavisc is an absorbable, clear, viscoelastic gel that is applied to tendons and peripheral nerves to reduce …

Read More

Visit FzioMed at these Conferences in 2013

  05/29 – 06/01 FESSH 2013 Federation of European Societies for Surgery of the Hand Gloria Convention Center Belek-Antalya, Turkey 10/02 – 10/04 Eurospine 2013 ACC Liverpool, United Kingdom 10/09 – 10/12 NASS 28th Annual Meeting North American Spine Society New Orleans, LA United States  

Read More

FzioMed receives approval for Oxiplex® in Russia

SAN LUIS OBISPO, California – January 22nd 2013 - FzioMed, a privately held medical device company based in San Luis Obispo, CA., is pleased to announce the approval of Oxiplex in Russia. Oxiplex is an absorbable, clear, viscoelastic gel that is applied during lumbar spine surgery immediately prior to wound closure.  Based on four studies …

Read More

FzioMed Announces 300,000 Units of Oxiplex Sold

SAN LUIS OBISPO, California – September 24, 2012   – FzioMed, Inc. (www.fziomed.com) announced that they have shipped the 300,000th unit of Oxiplex®. Oxiplex is approved outside of the United States in 68 countries worldwide and is distributed under the brand names Oxiplex®, Oxiplex®/SP and MediShield™. Oxiplex is an absorbable gel that is applied to spinal nerve …

Read More

Data from FzioMed’s Oxiplex® US Pivotal Clinical Study Published in Spine

Oxiplex Reduces Leg Pain, Back Pain and Associated Symptoms Following Lumbar Discectomy. SAN LUIS OBISPO, California – April 15th, 2012 - FzioMed, Inc. today announced the publication of results from the Oxiplex® pivotal clinical study in today’s issue of Spine, the leading international peer-review journal for study of the spine. Oxiplex is an absorbable gel …

Read More

Visit FzioMed at these Conferences in 2012

  May 28 - Jun 1 Spineweek 2012 Amsterdam, The Netherlands Jun 20 - 23 XVIIth Congress of the Federation of European Societies for Surgery of the Hand (FESSH) Antwerp, Belgium Oct 24 - 26 North American Spine Society (NASS) 27th Annual Meeting Dallas, TX  

Read More

FzioMed Receives CE Mark for DYNAVISC® Gel

New Adhesion Barrier Gel for Tendon and Peripheral Nerve Surgery SAN LUIS OBISPO, California – January 23, 2012 - FzioMed, Inc. is pleased to announce that it has received CE Mark approval to market DYNAVISC® adhesion barrier gel in Europe for tendon and peripheral nerve surgery. DYNAVISC is a clear, absorbable gel supplied ready-to-use in …

Read More

250,000 Units of Oxiplex Sold

SAN LUIS OBISPO, California – November 1, 2011 – FzioMed, Inc. (www.fziomed.com) announced that they have reached the 250,000 units sold mark. Oxiplex® is approved outside of the United States in over 70 countries worldwide under the brand names Oxiplex®, Oxiplex®/SP and MediShield™. Oxiplex is an absorbable gel that is applied to spinal nerve roots during …

Read More

FzioMed Announces New Website

SAN LUIS OBISPO, California – April 28, 2011 – FzioMed, Inc. announced today the launch of www.fziomed.com that has been transformed into an interactive tool to enhance the online experience of Healthcare Professionals, Distributors and Consumers searching for healthcare information.   The primary objective when designing the website was to provide an effective medium that would showcase the growing …

Read More

Visit FzioMed at these Conferences in 2011

Feb 2-4 British Association of Spine Surgeons (BASS) Edinburgh, UK Apr 9-13 American Association of Neurological Surgeons (AANS) Denver, CO USA Oct 1-6 Congress of Neurological Surgeons (CNS) Washington D.C. Oct 9-14 European Association of Neurological Surgeons (EANS) Rome, Italy Oct 19-21 Eurospine 2011 Milan, Italy Nov 1-5 North American spine Society (NASS) Chicago, IL …

Read More

200,000 Units of Oxiplex Sold

SAN LUIS OBISPO, California - November 29, 2010 - FzioMed, Inc. announced a major milestone in sales as the 200,000th unit of Oxiplex left its California manufacturing facility. Outside the U.S., Oxiplex also known as MediShield, is approved for sale in 63 countries including Canada, Australia, South Korea, Brazil and the entire European Union. "Over …

Read More

FzioMed Awarded $244,479 in Grants for Qualifying Therapeutic Development Projects

SAN LUIS OBISPO, California - November 2, 2010 - FzioMed, Inc. announced today that it was awarded cash grants totaling approximately $244,479 under the US Government's Therapeutic Discovery Project (QTDP) program. "We are delighted to receive this grant for our clinical program addressing unmet medical needs in the field of adhesion prevention," said John S. …

Read More

FzioMed Expands Oxiplex® Markets in Asia and South America

SAN LUIS OBISPO, California - March 30, 2010 - FzioMed, Inc. announced today expansion of Oxiplex® Adhesion Barrier Gel for Spine Surgery in both Asia and South America. In late 2009, FzioMed obtained approval for the Oxiplex® brand in South Korea and Brazil, and the Company recently appointed additional distributors in both countries. Product training …

Read More

FzioMed’s Oxiplex Gel for Spine Surgery Approved in Canada

SAN LUIS OBISPO, California - February 29, 2008 - FzioMed, Inc. today announced that Health Canada has approved the company's Oxiplex® gel for use in lumbar spine surgery. Oxiplex is an absorbable gel that is applied to spinal nerve roots during lumbar laminectomy, laminotomy and discectomy procedures. Oxiplex creates a temporary, protective barrier against the …

Read More

FzioMed Appoints Todd Fanning as Vice President of Sales

FzioMed Appoints Todd Fanning as Vice President of Sales SAN LUIS OBISPO, California - November 5, 2007 - FzioMed, Inc., a leader in surgical biomaterials, announced today the appointment of Todd P. Fanning to the position of Vice President of Sales. Mr. Fanning is a seasoned sales executive with over twenty years of experience growing …

Read More

FzioMed’s PMA Application for Oxiplex Gel Accepted for Filing by FDA

Oxiplex Targets Unmet Need; Application to Receive Expedited Processing SAN LUIS OBISPO, California - October 4, 2007 - FzioMed, Inc. announced today that the U.S. Food and Drug Administration (FDA) has completed its initial review of the company's Pre-Market Approval (PMA) application for Oxiplex spine surgery gel and has accepted the PMA for filing. FDA …

Read More

FzioMed Appoints Kevin Sidow to Board of Directors

SAN LUIS OBISPO, California - August 1, 2007 - FzioMed, Inc., a leader in surgical biomaterials, announced today the appointment of Kevin K. Sidow, former St. Francis Medical Technologies, Inc. President and CEO, to FzioMed's board of directors. While at St. Francis Medical, Mr. Sidow was responsible for overall operations and the achievement of milestones …

Read More

FzioMed Appoints James R. Peters to Board of Directors

SAN LUIS OBISPO, California - June 15, 2007 - FzioMed, Inc., a leader in surgical biomaterials, announced today the appointment of James R. Peters to the Company's board of directors. "Jim brings a wealth of knowledge and experience in the successful leadership of growing companies such as FzioMed," said Ron Haynes, Chairman of FzioMed, Inc. …

Read More

Laresse® Dermal Filler has Received Regulatory Approval in Australia from the Therapeutic Goods Administration (TGA).

SAN LUIS OBISPO, California - June 5, 2007 - FzioMed Inc. today announced that the company's Laresse® dermal filler has received regulatory approval in Australia from the Therapeutic Goods Administration (TGA). The TGA is the government agency responsible for regulating drugs and medical devices in Australia. Facial wrinkles, fine lines and creases are the result …

Read More

FzioMed Granted Patent Expanding Biomaterial Technology in the Field of Aesthetic Medicine, Soft Tissue Augmentation

SAN LUIS OBISPO, California - April 03, 2007 - FzioMed, Inc. announced today the issuance of United States patent 7,192,984 B2 which broadens coverage for the company's proprietary biomaterial technology in the field of aesthetic medicine. FzioMed's platform science involves the combination of biocompatible, absorbable polymers into innovative medical products. The new patent, entitled "Compositions …

Read More

Laresse® Dermal Filler Research Presented at Anti-Aging World Congress

SAN LUIS OBISPO, California - March 22, 2007 - FzioMed, Inc. announced today that a review of the company’s research on novel, synthetic dermal fillers is being presented at the Anti-Aging Medical World Congress (AAMWC) in Monte Carlo March 22-24, 2007. In 2006, FzioMed launched Laresse Dermal Filler, the first ultra-smooth, non-permanent, synthetic filler created …

Read More

Independent Studies on FzioMed’s Anti-Adhesion Gel Presented at Spine Meetings

SAN LUIS OBISPO, California - October 13, 2006 - FzioMed, Inc. announced today reports of positive clinical experiences by European surgeons using the company’s adhesion barrier gel to prevent postoperative adhesions from forming after back surgery. Presentations are being made at annual meetings of the Congress of Neurological Surgeons (CNS) in Chicago this week and …

Read More

FzioMed Unveils New Laresse® Dermal Filler Website

SAN LUIS OBISPO, California – October 10, 2006 – FzioMed, Inc., a leader in surgical biomaterials, announced today the launch of www.laresse.com, the official website for the company’s new, ultra-smooth Laresse® dermal filler. Laresse is the first of a family of dermal filler products based on FzioMed’s patented science. The company introduced Laresse in the …

Read More

FzioMed Launches New Laresse™ Dermal Filler in Europe

SAN LUIS OBISPO, California – July 13, 2006 – FzioMed, Inc. announced today the European Union launch of Laresse™ Dermal Filler, the first ultra-smooth, non-permanent filler created from the company’s patented polymer science. Laresse is a revolutionary new product for the correction of facial soft tissue contour deficiencies such as wrinkles and lines caused by …

Read More

FzioMed Reports Promising Results Using Oxiplex Gel to Reduce Perivascular Adhesions in Preclinical Artificial Disc Surgery

SAN LUIS OBISPO, California – May 9, 2006 – FzioMed, Inc. announced today the presentation of preclinical studies demonstrating that the company’s Oxiplex Gel was effective in reducing perivascular adhesions in artificial disc surgery. The poster presentation is being made at the Spine Arthroplasty Summit 6 (SAS6) of the Spine Arthroplasty Society held in Montreal, …

Read More

FzioMed Announces Publication in Fertility & Sterility Journal of Positive Clinical Results from Oxiplex/AP U.S. Trial in Adhesion Prevention

SAN LUIS OBISPO, California – November 28, 2005 – FzioMed, Inc. announced today the publication of positive results from a U.S. clinical trial of Oxiplex/AP for adhesion prevention in laparoscopic gynecological surgery. The peer-review article “Reduction of Postoperative Adhesions Following Laparoscopic Gynecological Surgery with Oxiplex/AP Gel: A Pilot Study” was published in the November 2005 …

Read More

FzioMed Announces Exclusive, Worldwide License for Bone Growth Peptide Portfolio

SAN LUIS OBISPO, California – November 10, 2005 – FzioMed, Inc. announced today that it has obtained the exclusive, worldwide license to a broad platform of patents and intellectual property covering novel, synthetic peptides from the University of Southern California (USC) for use in the regeneration of bone, cartilage and skeletal tissue. The worldwide license …

Read More

FzioMed Appoints Ron Ehmsen as Vice President of Clinical Affairs

SAN LUIS OBISPO, California – October 19, 2005 – FzioMed, Inc. announced today the expansion of its senior management team with the appointment of Ronald J. Ehmsen, ScD as Vice President of Clinical Affairs. Dr. Ehmsen will be responsible for overall planning and direction of the company’s clinical research activities and for ensuring the effective …

Read More

FzioMed Presents Preclinical Studies of Oxiplex Gel for Drug Delivery, Including Results of Novel Bone Growth Factor

SAN LUIS OBISPO, California – September 28, 2005 – FzioMed, Inc. announced today the presentation of preclinical studies demonstrating Oxiplex Gel as an effective drug vehicle, including results with a novel bone growth factor. The poster presentation is being made at the North American Spine Society (NASS) 20 th Annual Meeting held in Philadelphia, PA …

Read More

FzioMed Announces Positive Clinical Results Using Oxiplex/AP to Prevent Post-Surgical Adhesions in Endometriosis Patients

SAN LUIS OBISPO, California – September 14, 2005 – FzioMed, Inc. announces the presentation of clinical results from multi-center studies demonstrating that Oxiplex/AP significantly reduced the formation of postsurgical adhesions in patients undergoing laparoscopic surgery for treatment of endometriosis. The oral presentation is being made at IX World Congress on Endometriosis held in Maastricht, The …

Read More

FzioMed Granted Patent Expanding Oxiplex ® Technology in Drug Delivery and Hemostasis

SAN LUIS OBISPO, California – August 11, 2005 – FzioMed, Inc. announced today the issuance of United States patent 6,923,961 which broadens coverage for the company’s proprietary Oxiplex technology in the fields of drug delivery and hemostasis. Oxiplex is a versatile synthetic biomaterial developed by FzioMed for use in a wide variety of surgical specialties. …

Read More

FzioMed Appoints John S. Krelle as President and Chief Operating Officer

SAN LUIS OBISPO, California – July 19, 2005 – FzioMed, Inc. is pleased to announce the appointment of John S. Krelle as President and Chief Operating Officer of the privately held biomaterials company. Ronald F. Haynes, founder of FzioMed, will continue in his role as Chief Executive Officer and Chairman of the Board. As President …

Read More

FzioMed Reports Promising Results of Novel Bone Growth Factor in Preclinical Studies and Demonstrates Oxiplex Gel as Effective Drug Delivery Platform

SAN LUIS OBISPO, California – July 6, 2005 – FzioMed, Inc. announced today the presentation of preclinical studies demonstrating Oxiplex Gel as an injectable drug delivery system for a novel, synthetic peptide bone growth factor. The poster presentation is being made at the 12th International Meeting on Advanced Spine Techniques (IMAST) held in Banff, Alberta, …

Read More

FzioMed and Ethicon Sign Exclusive Distribution Agreement for Adhesion Barrier Product

SAN LUIS OBISPO, California – June 16, 2005 – FzioMed, Inc. announced today that it has signed an agreement appointing Ethicon, Inc., a global medical device company, as the exclusive distributor of FzioMed’s Oxiplex/AP, a bioabsorbable product for use in adhesion prevention in abdominal and pelvic surgeries. Under the agreement, Ethicon will have exclusive rights …

Read More

FzioMed Awarded New U.S. Patent For Oxiplex® Biomaterial Technology

SAN LUIS OBISPO, California - April 11, 2005 - FzioMed, Inc. announced today that it has been awarded a new United States patent covering the company's Oxiplex® technology. Oxiplex is a versatile polymer biomaterial developed by FzioMed for use in a wide variety of surgical specialties. The new patent, US 6,869,938, covers compositions of polyacids …

Read More

FzioMed Reports Preclinical Results Demonstrating Oxiplex/SP Adhesion Barrier Gel for Spine Surgery Does Not Inhibit Bone Healing

SAN LUIS OBISPO, California - June 30, 2004 - FzioMed, Inc. today announced the presentation of preclinical data showing that Oxiplex/SP Adhesion Barrier Gel for Spine Surgery does not inhibit healing in non-critical bone defects. The poster presentation is being made at the 11th International Meeting on Advanced Spine Techniques (IMAST) held in Bermuda from …

Read More

FzioMed Completes Pilot Clinical Trial of Oxiplex/AP Adhesion Barrier Gel in Laparoscopic Gynecological Surgery

SAN LUIS OBISPO, California - June 9, 2004 - FzioMed, Inc. today announced that the Company completed its United States pilot clinical trial of Oxiplex/AP Gel, an adhesion barrier for laparoscopic gynecological surgery. The randomized, multi-center trial was conducted to determine the safety of Oxiplex/AP Gel for the reduction of postoperative adhesions following laparoscopic gynecological …

Read More

FzioMed’s Adhesion Barrier, Oxiplex/AP® Gel, Reduces Extent and Severity of Adhesions After Gynecologic Surgery

SAN LUIS OBISPO, California - November 24, 2003 - FzioMed, Inc. will present clinical data of its Oxiplex/AP Gel, Adhesion Barrier for Abdominal/Pelvic Surgery, at the Annual Congress of the European Society of Gynaecological Endoscopy being held November 26 - 29, 2003 in Luxembourg. Richard Berg, PhD., Vice President of Research and Development, will present …

Read More

FzioMed to Present at Rodman & Renshaw Techvest Healthcare Conference

SAN LUIS OBISPO, California - October 16, 2003 - FzioMed, Inc. announced that Ronald F. Haynes, President and CEO of FzioMed, will present at the Rodman & Renshaw Techvest Healthcare Conference on Tuesday, October 21, 2003 at 6:20 pm. The conference will be held at the Long Wharf Marriott Hotel in Boston, MA and will …

Read More

FzioMed’s Oxiplex®/SP Adhesion Barrier Gel Improves Outcomes After Discectomy; Twelve-Month Clinical Trial Results Presented at World Spine II

SAN LUIS OBISPO, California - August 11, 2003 - FzioMed, Inc. is presenting additional follow-up data from the company's Oxiplex/SP Adhesion Barrier Gel clinical trial this week at the Council of Spine Societies' World Spine II conference in Chicago, Illinois. The results demonstrated that the benefits of using Oxiplex/SP Adhesion Barrier Gel in laminectomy, laminotomy …

Read More

FzioMed, Inc. Relocates and Expands Headquarters; New Production And Research Facility To Accommodate Continued Growth

SAN LUIS OBISPO, California - July 22, 2003 - FzioMed, Inc. announced today that it has relocated and expanded its corporate headquarters in San Luis Obispo, California.FzioMed's newly constructed facility includes larger areas for clean room manufacturing of the company's Oxiplex® products, expanded research and clinical trial management activities, and administrative offices."FzioMed is growing rapidly …

Read More

FzioMed Awarded New U.S. Patent For Oxiplex® Technology

SAN LUIS OBISPO, California - June 11, 2003 - FzioMed, Inc. announced today that it has been awarded United States patent 6,566,345 covering new formulations and delivery methods for the company's Oxiplex® technology. Oxiplex® is a unique polymer technology developed by FzioMed for use in applications such as post-surgical adhesion prevention. The patent covers new …

Read More

FzioMed Clinical Study Results For Oxiplex/SP Gel Published In Spine

SAN LUIS OBISPO, Calif. - May. 15, 2003 - FzioMed, Inc. announces that positive clinical study results of Oxiplex/SP Gel were published in the May 2003 issue of Spine (Volume 28, pages 1080-1088). The peer-review article reports the reduction of pain and radiculopathy with the use of Oxiplex/SP Gel after laminectomy, laminotomy and discectomy surgery. The …

Read More

FzioMed Receives Expanded Label Claims For Oxiplex® In Spine Surgery

SAN LUIS OBISPO, Calif. - Feb. 11, 2003 - FzioMed, Inc. announced today that it has received approval in Europe to expand the label claims for its Oxiplex®/SP Gel for use in spine surgery to include the reduction of pain and radiculopathy.Oxiplex®/SP Gel is a bioabsorbable gel that is applied during spine surgery as a …

Read More

FzioMed Presents Pre-Clinical Results On Oxiplex® For Adhesion Reformation In Adhesiolysis

SAN LUIS OBISPO, Calif. - Oct. 15, 2002 - FzioMed, Inc., a leading developer of absorbable biosurgery products, presented findings from its pre-clinical research to develop an anti-adhesion product for use in preventing post-surgical adhesions in abdominal/pelvic surgery. The presentation was made at the 58th Annual Meeting of the American Society for Reproductive Medicine held …

Read More

FzioMed, Inc. Announces Agreement with Medtronic Sofamor Danek

FzioMed to Supply Adhesion Prevention Product to Spine Industry Leader SAN LUIS OBISPO, Calif. - Aug. 26, 2002 - FzioMed, Inc., a leading developer of absorbable biosurgery products, announced today it has signed a distribution agreement with Medtronic Sofamor Danek, headquartered in Memphis, Tenn. FzioMed is engaged in the development and manufacture of advanced, absorbable …

Read More

FzioMed, Inc. Signs Distribution Agreement with DePuy AcroMed in Europe Leading Spine Company to Begin Selling FzioMed’s Oxiplex®/SP Gel Adhesion Prevention Product in Europe

SAN LUIS OBISPO, California - July 8, 2002 - FzioMed, Inc., the developer of Oxiplex® technology, announced today it has signed a European distribution agreement with DePuy AcroMed, Inc. FzioMed is engaged in the development and manufacture of advanced, absorbable biosurgery products. DePuy AcroMed, a Johnson & Johnson company, is a spine industry leader focused …

Read More

FZIOMED INC. (San Luis Obispo, CA) announced last week that it has begun a clinical trial to evaluate Oxiplex/SP, a bioresorbable product designed to reduce adhesions from lumbar surgery.

Medical Industry Today Date: 2/12/2001Companies: FzioMed Inc.Category: Devices The FDA recently approved the multicenter study of Oxiplex/SP, which is applied within the surgical site to reduce post-operative peridural scarring, or post-surgical adhesions. Adhesions are an abnormal, fibrous type of internal scar tissue that forms attachments, often between tissues and organs, tethering organs that normally would …

Read More

FzioMed, Inc. Announces Initiation of Clinical Trial for Adhesion Prevention Product in Spine Surgery

SAN LUIS OBISPO, California - February 5, 2001 - FzioMed, Inc. announced today that it has initiated a clinical trial of the company's Oxiplex™/SP spine surgery product. The U.S. Food and Drug Administration (FDA) recently approved FzioMed's Investigational Device Exemption (IDE) application to conduct a multi-center clinical pilot study of the new product. Oxiplex™/SP is …

Read More

FzioMed, Inc. Granted Two New Patents for Oxiplex™ Technology

Actions by U.S. Patent Office Extend FzioMed's Coverage for Oxiplex™ Technology in Surgical Adhesion Prevention SAN LUIS OBISPO, California - January 15, 2001 - FzioMed, Inc. announced today that it has received its seventh United States patent for the company's Oxiplex™ technology. The company also received a notice of allowance for an additional patent covering …

Read More

FzioMed, Inc. Achieves International Quality Certification

Facility Certified to ISO 9001, EN46001 and ISO 13485 Standards SAN LUIS OBISPO, California - December 19, 2000 - FzioMed, Inc., the developer of Oxiplex™ technology, announced today it has received ISO 9001 certification. FzioMed's Oxiplex™ technology is used to produce bioresorbable materials for surgical and medical applications. FzioMed, Inc. has received certification from KEMA …

Read More